'Ncl' diaporamas de présentation

Coordination of movements

Cerebellum. Coordination of movements. Margo ant., incisura cerebelli ant. Margo post., incisura cerebelli post. Vermis Hemispheres Pars flocculonodularis Folia, lobuli, lobi. Fissura prima. Lobus ant. Lobus flocculonod. Lobus post. Fissura posterolat. Developmental anatomy.

667 views • 66 slides

Introduction

Introduction. Dennis Shea. NCAR is sponsored by the National Science Foundation. Workshop Overview. Objective comfortable with NCL ; minimize learning curve workshop will not make you an expert access, process and visualize data. Labs important: you must invest the time

620 views • 53 slides

Introduction

Introduction. Dennis Shea. NCAR is sponsored by the National Science Foundation. Workshop Overview. Objective comfortable with NCL ; minimize learning curve workshop will not make you an expert access, process and visualize data. Labs important: you must invest the time

533 views • 45 slides

Coordination of movements

Cerebellum. Coordination of movements. Vermis Hemispheres Folia, lobuli, lobi. Pars flocculonodularis. Fissura prima. Lobus ant. Lobus flocculonod. Lobus post. Fissura posterolat. Developmental anatomy. Archi- cerebellum. Afferents from vestib. labyrinth fish, amphibians.

469 views • 43 slides

Brainstem

Brainstem. Mesencephalon Pons Medulla oblongata. ? nuclei of CN III - XII ? connection to the cerebellum ? large reticular formation. CN III CN IV, V CN VI, VII, VIII CN IX, X, XI CN XII. Ventral aspect. ? IV. ventricle ? roof of the IV. ventricle:

343 views • 29 slides

Clinical Trials: Challenges and Opportunities

Clinical Trials: Challenges and Opportunities. Erika Augustine ,MD University of Rochester Medical Center October 31, 2012. Current state of treatment in NCLs. No FDA approved disease-modifying therapy for any NCL Symptomatic treatments At least 5 recent or ongoing clinical trials

330 views • 26 slides

APOPTOTIC DEFECTS IN NCL

Use of the oral antiapoptotic agent Flupirtine as a treatment strategy in human INCL, LINCL, JNCL and CLN6-deficient vLINCL. APOPTOTIC DEFECTS IN NCL. Anti-apoptotic effects of intact CLN3 is firmly established in humans : 1. By EM and TUNEL of human JNCL brain (Lane et al,. 96).

375 views • 24 slides

An automatic Procedure for Neighbor Cell List Definition in Cellular Networks

314 views • 21 slides

Tour of NCL Website

Tour of NCL Website. www.ncl.ucar.edu. Modified by R. Grotjahn 2016 03 04. NCL capabilities:. Functions Visualization (many graphics, map overlays, 3-D, etc.) Mathematical (divergence, regridding , EOFs, filtering, etc.) Statistical (correlation, spectra, wavelets, kmeans , etc.)

182 views • 18 slides

IT support for NICE NICE Committee of Experts 27

176 views • 17 slides

NCL Website Tour ncl.ucar

280 views • 16 slides

NCL Website Tour ncl.ucar

279 views • 16 slides

Center for Strategic Scientific Initiatives (CSSI)

Center for Strategic Scientific Initiatives (CSSI). Presented By: Michelle Berny-Lang. Overview of Mission and Purpose. Center for Strategic Scientific Initiatives (CSSI) Overview. CSSI Office of the Director Office of Cancer Nanotechnology Research (OCNR)

160 views • 16 slides

Post Processing Tools

Post Processing Tools. Sylvia Murphy murphys@ucar.edu National Center for Atmospheric Research. Purpose. Provide a brief introduction into the suites of utilities available to visualize and data process CCSM output. Outline. NCL CCSM Support Web Site Graphics Data Processing CMPS NCO

169 views • 16 slides

Namma Container Lines

Namma Container Lines. About us. Company. Services. Agency network. About us. Company. Contact us. Services. Agency network. Contact us. About us. About us. Namma Container Lines ( NCL) , EGYPT is a subsidiary of Nesma Holding Group in KSA .

257 views • 12 slides

Namma Container Lines

Namma Container Lines. About us. Company. Services. Agency network. About us. Company. Contact us. Services. Agency network. Contact us. About us. About us. Namma Container Lines ( NCL) , EGYPT is a subsidiary of Nesma Holding Group in KSA .

558 views • 12 slides

Scott McNeil, Ph.D. ncl@ncifcrf nclncer

Public Meeting on Nanotechnology Materials in FDA-Regulated Products October 10, 2006. Scott McNeil, Ph.D. ncl@ncifcrf.gov http://ncl.cancer.gov. Preclinical Characterization of Nanoparticles. Cancer Nanotechnology Program.

218 views • 7 slides